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Abstract
Innate immune activation via Toll-like receptors (TLRs), although critical for host defense against infection, must be
regulated to prevent sustained cell activation that can lead to cell death. Cells repeatedly stimulated with
lipopolysaccharide (LPS) develop endotoxin tolerance making the cells hypo-responsive to additional TLR stimulation.
We show here that DOK3 is a negative regulator of TLR signaling by limiting LPS-induced ERK activation and cytokine
responses in macrophages. LPS induces ubiquitin-mediated degradation of DOK3 leading to SOS1 degradation and
inhibition of ERK activation. DOK3 mice are hypersensitive to sublethal doses of LPS and have altered cytokine responses in
vivo. During endotoxin tolerance, DOK3 expression remains stable, and it negatively regulates the expression of SHIP1,
IRAK-M, SOCS1, and SOS1. As such, DOK3-deficient macrophages are more sensitive to LPS-induced tolerance becoming
tolerant at lower levels of LPS than wild type cells. Taken together, the absence of DOK3 increases LPS signaling,
contributing to LPS-induced tolerance. Thus, DOK3 plays a role in TLR signaling during both naı ¨ve and endotoxin-induced
tolerant conditions.
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Introduction
Toll-like receptors (TLRs) are pattern recognition receptors
used by cells of the innate immune system to detect pathogen-
associated molecular patterns (PAMPs), including the bacterial cell
wall component lipopolysaccharide (LPS), which combines with
the small molecule MD2 to activate TLR4 [1]. LPS, in turn,
initiates downstream intracellular signaling events, including the
activation of NF-kB and of the mitogen activated protein kinases
(MAPKs) ERK, JNK, and p38 [1,2,3,4]. Activation of these
signaling components leads to the production of pro-inflammatory
cytokines, including tumor necrosis factor a (TNFa), interleukin-
1b (IL-1b), and interleukin-6 (IL-6).
Although TLRs are essential for initiating activation of innate
defenses and for enhancing adaptive responses to pathogens,
inappropriate regulation of cytokine production contributes to
chronic inflammation and to systemic autoimmune diseases [5]. In
septic patients and experimental animal models of sepsis
stimulated by injection of high doses of LPS, massive cytokine
production may be lethal [6]. The neutrophils, monocytes, and
macrophages of septic patients develop a refractory state to
subsequent LPS exposure and become incapable of producing
cytokines at levels comparable to those prior to sepsis [7]. This
state of unresponsiveness is termed endotoxin tolerance and
prevents overstimulation from continuous exposure to LPS.
However, endotoxin tolerant cells are unable to respond to
subsequent TLR challenges leads to up to three weeks of immune
paralysis in humans. During this time, significant morbidity occurs
in hospitalized patients due to super-infections; therefore, de-
termining mechanisms that regulate endotoxin tolerance is critical
to identify therapeutics that could reverse LPS-induced immune
paralysis.
Despite significant understanding of mechanisms that regulate
TLR responses in general, we have a relatively limited un-
derstanding of mechanisms that contribute to the development or
maintenance of LPS tolerance. Several proteins, including IL-1
receptor-associated kinase M (IRAK-M) [8], Src homology 2
(SH2) domain-containing inositol-5-phosphatase 1 (SHIP1) [9],
and suppressor of cytokine signaling 1 (SOCS1) [10], participate in
LPS tolerance. IRAK-M is an inhibitor of the IRAK-1/IRAK-4
cascade and mice deficient for IRAK-M demonstrate an increased
inflammatory response to bacterial infection [8]. Moreover,
IRAK-M-deficient macrophages are significantly impaired in the
development of LPS tolerance [8]. SHIP1 inhibits LPS-induced
activation of MAPKs and cytokines [11] and regulates IRAK-M
expression during endotoxin tolerance development [12]. Fur-
thermore, SHIP1-deficient Bone Marrow Macrophages (BMM)
fail to develop LPS tolerance [9], although others have reported
that SHIP1 may also promote TLR4-mediated cytokine pro-
duction [13]. Similarly, SOCS-1 is required for tolerance [14] and
negatively regulates TLR4 MyD88-dependent signaling [15]
causing SOCS-1-deficient mice to be highly susceptible to LPS
[10]. In spite of these advances, additional molecular mechanisms
that regulate LPS tolerance are yet to be defined.
Downstream of tyrosine kinases (DOK) comprise a growing
family of adaptor molecules that function to limit tyrosine kinase-
mediated signaling downstream of numerous immunoreceptors,
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TLR responses has only been partially defined. DOK1 and
DOK2 function as negative regulators of LPS-induced ERK
activation and TNFa production in macrophages, but they fail to
regulate other TLR responses mediated by TLR2, TLR3 or
TLR9 [17]. DOK3 is also expressed in myeloid cells but has
a unique cytoplasmic domain that does not bind to Ras GTPase
like DOK1 or DOK2 [18,19]. Moreover, previous reports in B
cells demonstrate that DOK3 negatively regulates JNK activation,
but not ERK, in response to B-cell receptor (BCR) stimulation.
The structural and functional differences between DOK3 and
other DOK isoforms suggest that DOK3 has non-redundant roles
in regulating immunoreceptor and possibly TLR signaling
[20,21,22]. The aim of this study was to determine the role of
DOK3 in regulating TLR responses and endotoxin tolerance in
macrophages.
Results
DOK3 Expression is Reduced during Macrophage
Stimulation with LPS
DOK1 and DOK2 have been previously shown to participate
in the negative regulation of LPS in macrophages [17]; however,
the role of DOK3 has not been described. To assess the role of
DOK3 in macrophage responses to TLR signaling, changes in
DOK3 protein expression were examined following TLR
stimulation of bone marrow macrophages (BMM). Whereas
low doses of LPS (1 ng/ml and 10 ng/ml) failed to induce any
changes in DOK proteins, higher doses of LPS (100 ng/ml or
1 mg/ml) significantly reduced the expression of DOK3
(Figure 1A and B). The LPS-triggered decrease in DOK3
expression was greater than decreases of other DOK isoforms.
DOK1 expression was partially reduced at the highest dose of
LPS in a manner similar to peritoneal macrophages [17];
whereas DOK2 expression remained stable at all doses
(Figure 1B). We also tested additional TLR ligands, including
ligands for TLR9 (CpG), TLR3 (poly (I:C)), and TLR2
(Zymosan) in the regulation of DOK3 expression. Although
ligands for TLR3 or TLR2 failed to alter DOK3 expression,
CpG triggered decreases in DOK3 expression with maximal loss
at 60 min (Figure 1B) indicating that DOK3 is regulated
downstream of TLR4 and TLR9 signaling in BMM.
Decreases in DOK3 expression induced by LPS occurred as
early as 20 minutes but were maximal at 60 minutes suggesting
that new protein synthesis might be required to regulate DOK3
expression. To investigate this possibility, we pretreated macro-
phages with the protein synthesis inhibitor, cycloheximide, prior to
LPS stimulation. As seen in Figure 1C, DOK3 remained stable
over 40 minutes in resting cells treated with cycloheximide but was
significantly reduced after LPS stimulation even in the presence of
cycloheximide. Thus, new protein synthesis was not necessary for
decreases in DOK3 expression induced by LPS.
To determine whether LPS may induce DOK3 cellular
translocation, localization of DOK3 after 1 hour of LPS
stimulation was performed by confocal microscopy (Figure 1D).
In resting cells, DOK3 was diffusely localized throughout the
cytoplasm and the staining pattern remained stable following
stimulation with a low dose of LPS (1 ng/ml). However, at doses
of LPS that induce loss of DOK3 (1 mg/ml), we found DOK3
staining was significantly reduced and failed to be localized into
discreet compartments. These results indicate that the observed
reduction of DOK3 in cell extracts after LPS stimulation did not
reflect sequestration of DOK3 into insoluble cellular compart-
ments. Thus, degradation of DOK3 is the most likely explana-
tion for DOK3 loss following treatment of cells with high dose of
LPS.
LPS-induces Degradation of DOK3 in a Phosphorylation
Independent Manner
To determine whether LPS induces DOK3 degradation within
proteosomes and lysosomes, BMM were treated with the
proteosome inhibitor, MG132, or the lysosome inhibitor, NH4Cl.
We found that both MG132 and NH4Cl blocked LPS-induced
DOK3 degradation leading to the accumulation of a higher
molecular weight DOK3 species (Figure 2A). These results imply
that LPS induces the degradation of DOK3 within proteosomes
and lysosomes, leading to reduced DOK3 expression.
The contribution of DOK3 phosphorylation to degradation was
investigated by treating BMM with Ly294002 (PI3K inhibitor),
PP2 (Src inhibitor), BAY 61–3606 (Syk inhibitor), or LFM-A13
(Btk inhibitor) for 30 minutes prior to LPS stimulation. Phosphor-
ylated DOK3 was present in resting cells treated with inhibitors of
PI3K, Syk and Btk but was not evident when Src family kinases
were inhibited with PP2 (Figure 2B, bottom panel). These data
suggest that DOK3 is constitutively tyrosine-phosphorylated by
a member of the Src family of protein tyrosine kinases in resting
macrophages. Furthermore, LPS-induced DOK3 degradation
occurred in PP2 treated cells indicating that phosphorylation is
not necessary for degradation (Figure 2B). Taken together, Src
kinases participate in the phosphorylation of DOK3, but LPS-
mediated DOK3 degradation is phosphorylation independent.
LPS Induces Ubiquitination of DOK3
To elucidate the molecular mechanism underlying LPS-induced
degradation of DOK3, we examined the ubiquitination of DOK3
in response to LPS stimulation in the presence of MG132, which
inhibits the degradation of ubiquitin-conjugated proteins. DOK3
was immunoprecipitated from LPS-stimulated BMM cell lysates
and probed with antibodies to ubiquitin. The results show that in
the presence of MG132, ubiquitinated DOK3 was observed as
early as 10 minutes and peaked at 20 minutes after LPS
stimulation (Figure 3A). Immunoblot of DOK3 confirmed that
MG132 blocked the LPS-induced degradation seen in the control
cells.
To verify that DOK3 was ubiquitinated, an ubiquitin-binding
GST-fusion protein was used to co-precipitate DOK3. The
ubiquitin binding domain of Cbl (Cbl-Uba) has a high binding
affinity for ubiquitinated proteins [23], and a GST-Cbl-Uba
(amino acids 887–928) fusion protein was generated to precipitate
ubiquitinated proteins. Unlike GST alone, GST-Cbl-Uba fusion
protein was able to pull down ubiquitinated proteins (Figure 3B)
from LPS treated BMM and specifically precipitated DOK3
(Figure 3C). Co-precipitation was observed as early as 10 minutes
and peaked at 40 minutes following LPS simulation (Figure 3C).
These data suggest that LPS induces ubiquitination of DOK3, or
the association of DOK3 with ubiquitinated proteins, and
subsequent degradation of DOK3 in BMM.
Previous studies have indicated that LPS stimulation induces the
activation of the E3 ligase Cbl-b, which is required to limit TLR
signals [24,25]. Therefore, taking a candidate approach, Cbl-b was
investigated for association with DOK3 following LPS stimulation.
Cbl-b co-immunoprecipitated with DOK3 at 10 to 20 min in
LPS-stimulated BMM (Figure 3D) indicating that LPS stimulation
promotes the association of DOK3 with the E3 ligase, Cbl-b.
Taken together, these data suggest that LPS induces the
association of Cbl-b and DOK3, with subsequent DOK3
ubiquitination and degradation.
DOK3 Limits LPS Responses
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In HEK 293 cells, DOK3 has been shown to inhibit the Ras-
Erk pathway by sequestering Grb2 downstream of protein-tyrosine
kinases [19]. However, this function of DOK3 in regulating TLR
signaling in macrophages has not been described. To determine
the role of DOK3 in regulating ERK activation downstream of
LPS, we generated a stable DOK3 knock-down in RAW264.7
macrophage cells with shRNA lentiviral transduction. Decreased
DOK3 expression was confirmed by western blot of cell lysates of
DOK3 knock down cells as compared to control luciferase shRNA
(Figure 4A). In DOK3 knock-down cells, LPS stimulation induced
earlier ERK activation compared to control cells (Figure 4A). To
ensure that the increases in LPS-induced ERK activation were not
due to off-target effects of the lentivirus, BMM were derived from
DOK3-deficient mice [26] and stimulated with LPS. DOK3-
deficient BMM demonstrated increased LPS-induced ERK
activation compared to wild type macrophages (Figure 4B). These
results suggest that DOK3 protein levels inhibit LPS-induced
ERK activation.
To test this hypothesis, DOK3 degradation was blocked with
MG132 prior to LPS stimulation, and ERK phosphorylation was
determined by immunoblotting. In control cells treated with
Figure 1. LPS stimulation of macrophages induces DOK3 degradation. BMM were stimulated with (A) 1, 10, or 100 ng/ml LPS; or (B) 1 mg/ml
LPS (TLR4 ligand), 0.5 mM CpG (TLR9 ligand), 25 mg/ml Poly (I:C) (TLR3 ligand), or 10 mg/ml Zymosan (TLR2 ligand) for the indicated time and cell
lysates were immunoblotted for DOK1, DOK2, DOK3, and GAPDH. (C) BMM were treated with 10 mg/ml of the translational inhibitor cycloheximide
during LPS stimulation. Data are representative of three independent experiments. (D) BMM cells were stimulated with LPS (1 ng/ml and 1 mg/ml) for
1 h. The cells were fixed, permeabilized, and immunofluorescent staining for DOK3 (red) and DAPI (blue) was performed and visualized with a Leica
TCS NT Confocal microscope. Bar is 10 mm.
doi:10.1371/journal.pone.0039967.g001
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DOK3 degradation, with a peak at 20 minutes consistent with
degradation of 50% of DOK3. Prevention of protein degradation
by MG132, including DOK3, resulted in an inhibition of ERK
activation (Figure 4C). Moreover, over-expression of DOK3
(FLAG-tagged DOK3) in RAW264.7 macrophage cells attenu-
ated LPS-induced ERK activation (Figure 4D). Interestingly, LPS
stimulation induced the degradation of over-expressed FLAG-
Figure 2. LPS stimulation in macrophages induces phosphorylation-independent degradation of DOK3. (A) BMM were stimulated with
1 mg/ml LPS and DMSO (control), proteasomal inhibitor (10 mM MG132), or lysosomal inhibitor (20 mM NH4Cl) or (B) BMM were stimulated with 1 mg/
ml LPS in the presence of Src inhibitor (PP2), Syk inhibitor (Bay), PI3 kinase inhibitor (Ly294002), or Btk inhibitor (LFM) for the indicated time and cell
lysates were immunoblotted for DOK3 and GAPDH. DOK3 phosphorylation was determined by immunoprecipitation (IP) with an anti-
phosphotyrosine antibody and immunoblotting (IB) for DOK3. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0039967.g002
Figure 3. DOK3 is ubiquitinated through interaction with the E3 ligase Cbl-b in response to LPS stimulation. (A) BMM were stimulated
with 1 mg/ml LPS 610 mM MG132 for the indicated time, and ubiquitinated DOK3 was determined by immunoprecipitating with an anti-DOK3
antibody and immunoblotting with an anti-ubiquitin antibody. DOK3 immunoblot confirms degradation of DOK3 in control but not MG32 treated
cells. H.C., heavy chain of IgG (B) GST-Cbl-Uba, comprised of GST and 887–928 amino acids (aa) of Cbl-b, was used to immunoprecipitate
ubiquitinated proteins (bottom panel shows input amount of GST or GST-fusion). (C) GST-Cbl-Uba pulldown of LPS stimulated BMM lysates were
immunoblotted for DOK3. Input amount of GST-fusion protein is the bottom blot. (D) DOK3 immunoprecipitation of LPS treated BMM
immunoblotted for Cbl-b and DOK3. wcl, whole cell lysate Data are representative of three independent experiments.
doi:10.1371/journal.pone.0039967.g003
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activation was delayed until 40 minutes, when FLAG-DOK3 was
nearly degraded. Taken together, the expression of DOK3, as
controlled by LPS-induced ubiquitination and degradation,
regulates ERK activation.
LPS Induces SOS1 Degradation in a DOK3-dependent
Manner
In HEK293 cells, DOK3 serves to regulate Ras-ERK activation
by binding to and sequestering Grb2 away from SOS1, a Ras
guanine nucleotide exchange factor [19]. To address whether
a similar mechanism was operative in LPS-stimulated BMM,
DOK3 was immunoprecipitated and protein complexes immuno-
blotted for Grb2 and SOS1 (Figure 5A). In resting BMM and at 10
minutes after LPS stimulation, DOK3, Grb2, and SOS1 co-
immunoprecipitated with the use of either anti-DOK3 (Figure 5A)
or anti-Grb2 (Figure 5B) antibodies. At 20 minutes, significantly
less DOK3 co-precipitated with Grb2 consistent with DOK3
degradation, while the association of GRB2 and SOS1 remained
intact (Figure 5B). Interestingly, SOS1 also showed significant
reductions after LPS stimulation that paralleled DOK3 degrada-
tion (Figure 5B). These findings suggest that LPS stimulation leads
to reductions in SOS1 in addition to DOK3.
To address this hypothesis, SOS1 levels were evaluated in
DOK3-deficient BMM after LPS stimulation. In wild type BMM,
SOS1 levels were significantly reduced by 20 minutes and
undetectable at 60 minutes after LPS treatment (Figure 5C).
However, SOS1 levels remained stable after LPS treatment in
DOK3-deficient BMM (Figure 5C). Therefore, SOS1 appears to
be degraded in a DOK3-dependent manner after LPS stimulation.
To evaluate this possibility, we treated wild type BMM with
NH4CL to prevent lysosome-mediated protein degradation.
NH4Cl treatment prevented SOS1 degradation in wild type cells
similar to the stable SOS1 levels observed in DOK3-deficient cells
(Figure 5D). Thus, LPS induces SOS1 degradation in the lysosome
in a DOK3-dependent manner in BMM, a mechanism of SOS1
regulation not previously appreciated.
DOK3 Alters LPS-induced Cytokine Production and
Contributes to Survival in vivo
NF- kB activation is a critical component of TLR signaling and
leads to the production of several cytokines. In order to measure
the activation of NF-kB, the amount of IkBa was determined
following LPS stimulation in wild type and DOK3-deficient
BMM. In response to LPS, DOK3-deficient BMM showed more
rapid and sustained degradation of IkBa compared to wild type
cells (Figure 6A), indicating that DOK3 negatively regulates NF-
kB activation downstream of LPS stimulation. TNFa, IL-6, IL-10
and IL-1b are important mediators of LPS-induced inflammation;
therefore, these cytokines were measured in conditioned media
from LPS-stimulated (1 mg/ml) wild type and DOK3-deficient
BMM. While there was little difference in LPS-induced TNFa and
IL-6 between strains, IL-10 and IL-1b production was significantly
increased in DOK3-deficient BMM (Figure 6B). In sum, DOK3
negatively regulates NF-kB activation and the production of the
pro-inflammatory cytokine IL-1b and the anti-inflammatory IL-10
following stimulation with LPS.
To investigate the role of DOK3 in vivo, wild type and DOK3-
deficient mice were challenged with an intraperitoneal (i.p.)
injection of 5 mg/kg LPS and blood was drawn prior to and
1 h following the administration of LPS. Interestingly, DOK3
2/2
mice had a significantly increased TNFa and IL-1b response,
while IL-6 and IL-10 levels were decreased in vivo compared to wt
(Figure 6C). Furthermore, mice were challenged i.p. with a sub-
lethal dose (70 mg/kg) of Salmonella typhosa LPS and monitored for
survival over 7 days. All mice became ill but 100% of wild type
mice recovered, while all DOK3-deficient mice succumbed
(Figure 6D). Thus, DOK3 plays a role both in vitro and in vivo
limiting LPS-induced cytokine responses and sepsis.
Figure 4. LPS-induced degradation of DOK3 mediates ERK activation. (A) RAW264.7 macrophages, transduced with 23 nt plus hairpin
shRNA designed to knock down DOK3 or a control luciferase knock down, were lysed and decreased DOK3 expression was confirmed by
immunoblotting. Cells were and stimulated with 1 mg/ml LPS for the indicated time and cell lysates were immunoblotted for pERK, ERK, and GAPDH.
(B) Wild type (WT) or DOK3-deficient BMM were stimulated with 1 mg/ml LPS and cell lysates were immunblotted for pERK, ERK, and the GAPDH. The
amount of DOK3 and Grb2 was detected by immunoblot in cell lysates. (C) BMM cells were pretreated with DMSO or 10 mM MG132 and stimulated
with 1 mg/ml LPS for the indicated times. Lysates were immunoblotted for phosphorylated ERK (pERK), ERK, and DOK3. (D) RAW264.7 macrophages
transfected with FLAG-tagged mouse DOK3- were stimulated with 1 mg/ml LPS for the indicated time and cell lysates were immunoblotted for pERK,
ERK, FLAG and GAPDH. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0039967.g004
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Tolerance
An initial exposure to LPS induces a transient state of hypo-
responsiveness to a subsequent challenge with LPS, termed
endotoxin tolerance. To induce tolerance, BMM were pretreated
with 1 mg/ml LPS, rested in fresh media, re-challenged with LPS,
and ERK activation was evaluated to confirm tolerance.
Compared to naı ¨ve cells where LPS induced ERK phosphoryla-
tion, re-stimulation of LPS-pretreated cells failed to activate ERK,
indicating that the cells are tolerant towards LPS (Figure 7A).
Unlike naı ¨ve cells stimulated with LPS, tolerant BMM re-
stimulated with LPS maintain stable DOK3 expression.
To determine whether DOK3 remained associated with Grb2
in LPS-tolerant BMM, wild type tolerant BMM were re-
challenged with LPS and lysates were immunoprecipitated with
Figure 5. DOK3 associates with Grb2 and SOS1 and promotes SOS1 degradation in response to LPS. BMM were stimulated with 1 mg/
ml LPS for indicated time and cell lysates were immunoprecipitated with (A) anti-DOK3 antibody or (B) anti-Grb2 antibody followed by
immunoblotting for DOK3, Grb2, and SOS1. As a control, isotype matched antibody was used for immunoprecipitation (Con Ig). Protein levels were
quantified using Image J. (C) Wild type and DOK3
2/2 BMM were stimulated with 1 mg/ml LPS for indicated time and immunoblotted for SOS1 and
GAPDH. (D) BMM were treated with NH4CL or PBS (control) and were stimulated with 1 mg/ml LPS and immunoblotted for SOS1 and GAPDH. Data are
representative of three independent experiments.
doi:10.1371/journal.pone.0039967.g005
Figure 6. DOK3 alters LPS-induced inflammatory cytokine expression and is required for survival after LPS challenge. (A) Wild type
and DOK3-deficient BMM were stimulated with 1 mg/ml LPS and cell lysates were immunoblotted for IkBa and GAPDH. (B) Wild type and DOK3-
deficient BMM were treated with 1 mg/ml LPS for 16 h and amounts of IL-10, IL-6, TNFa, and IL-1b in conditioned media were determined by ELISA.
(C) Serum was collected from WT and DOK3
2/2 mice prior to and 60 min. following challenge with 5 mg/kg LPS and serum IL-6, TNFa, IL-10 and IL-1b
levels were determined by ELISA. (D) DOK3
2/2 mice are hypersensitive (P,0.0027) compared to WT mice following i.p. challenge with a sublethal LPS
dose (70 mg/kg). The * in C and D indicates a significant difference (P,0.05) between cell type/strain and results are expressed as means 6 S.D.
doi:10.1371/journal.pone.0039967.g006
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tolerant wild type BMM re-challenged with LPS showed
constitutive and stable association of Grb2 with DOK3
(Figure 7B). Additionally, SOS1 levels remained stable during
tolerance (Figure 7C, WT). As compared to wild type tolerant
BMM, SOS1 protein levels were further increased in DOK3-
deficient LPS-tolerant BMM (Figure 7C). Taken together, DOK3
and SOS1 are stabilized during tolerance.
DOK3–deficient BMM have Increased Sensitivity to
Endotoxin Tolerance
Because DOK3 levels remain stable during endotoxin toler-
ance, we next investigated the role of DOK3 in tolerance. WT and
DOK3
2/2 BMM were initially treated with 10 ng/ml or 100 ng/
ml of LPS to induce tolerance. Cells were subsequently re-
challenged with the same dose of LPS and intracellular TNFa
levels were quantified by intracellular flow cytometry. WT BMM
challenged with 10 ng/ml or 100 ng/ml of LPS displayed a partial
suppression of TNFa after re-stimulation (Figure 8A, Blue)
compared to naı ¨ve cells (Red). In contrast, DOK3-deficient
BMM acquired LPS tolerance at low doses of LPS with
suppression of TNFa expression at 10 and 100 ng/ml of LPS
(Figure 8A and 8B). Thus, in the absence of DOK3, BMM are
more sensitive to tolerance induction by LPS.
To investigate the molecular mechanism of enhanced toler-
ance in DOK3-deficient BMM, we assessed the expression of
several mediators of endotoxin tolerance, including SH2-contain-
ing Inositol phosphatase-1 (SHIP1) [11,12], Interleukin-1 re-
ceptor-associated kinase in myeloid cells (IRAK-M) [8], and
Suppressor of cytokine signaling -1 (SOCS1) [10]. In WT and
DOK3-deficient BMM, tolerance increased expression of SHIP1,
IRAK-M, and SOCS1 compared to naı ¨ve cells, supporting their
proposed role in tolerance (Figure 8C). Furthermore, comparing
the quantified increased protein levels in tolerant cells compared
to naı ¨ve levels indicates that DOK3-deficient tolerant BMM had
substantially higher expression of SHIP1, IRAK-M, and SOCS1
expression compared to WT cells (Figure 8C). These findings
suggest that in the absence of DOK3, BMM are more sensitive
to LPS-induced ERK activation with subsequent upregulation of
a gene expression profile that promotes endotoxin tolerance.
Discussion
Innate immunity is critical for the first line of defense against
bacterial and viral pathogens and is required to control early
infections. TLR signaling stimulates the innate immune response
by producing proinflammatory cytokines including TNFa, IL-6,
and IL-1b, which leads to additional immune cell activation [27].
If left unchecked, the persistent cytokine responses to sustained
TLR stimulation can lead to a cytokine storm resulting in sepsis
and death. To prevent this result, persistent LPS stimulation can
lead to a state of hypo-responsiveness to additional TLR stimuli.
During this state, which can last up to 3 weeks in humans, the host
is at high risk of super-infection with additional bacteria or virus.
During sepsis, this state of immunosuppression is associated with
substantial additional morbidity and mortality. Although some
important regulators of tolerance have been indentified, our
understanding of mechanisms by which tolerance is prevented or
resolved are incompletely defined.
We show here that DOK3 in macrophages has a non-
redundant role in TLR signaling through TLR4 and TLR9 and
that DOK3 has a regulatory role in preventing LPS induced
tolerance. Our findings suggest a model in which LPS stimulation
down-regulates the expression of DOK3 by targeting it for
degradation via the ubiquitin-mediated pathway, and this process
is independent of DOK3 phosphorylation (Figure 9). Moreover,
SOS1 is targeted to the lysosome in a DOK3-dependent manner
following LPS stimulation thus limiting ERK activation. Conse-
quently, LPS induces enhanced ERK activation in the absence of
DOK3. DOK3 also negatively regulates LPS induced NF-kB
activation and the cytokines IL-1b and IL-10 in vitro and TNF
and IL-1b in vivo. However, in vivo DOK3-deficient animals had
decreased IL-6 and IL-10 production in response to LPS
compared to wild type. While the contribution of LPS responses
from in vitro data is representative of bone marrow derived
macrophages, multiple immune cells including monocytes, perito-
neal macrophages, bone marrow macrophages and B cells
contribute in vivo. The fact that DOK1 and DOK2 are degraded
Figure 7. DOK3 and SOS1 are stable during LPS-induced tolerance. (A) BMM were pretreated with 1 mg/ml LPS for 18 hours, rested in fresh
media for 2 hours and re-stimulated along with naı ¨ve cells with 1 mg/ml LPS for indicated time and cell lysates were immunoblotted for DOK3, pERK,
ERK, and GAPDH. (B) Tolerant BMM were stimulated with 1 mg/ml LPS and cell lysates were immunoprecipitated with anti-DOK3 antibody and
immunoblotted for Grb2 and DOK3. (C) Tolerant wild type and DOK3-deficient BMM were re-stimulated with 1 mg/ml LPS and lysates immunoblotted
for SOS1 and JNK (loading control). Data are representative of three independent experiments.
doi:10.1371/journal.pone.0039967.g007
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in bone marrow macrophages where we see a partial reduction in
DOK1 but no change in DOK2 protein expression suggests that
DOK3 has a non-redundant role in limiting TLR responses in
a cell-type specific manner. Additionally, as compared to DOK1
and DOK2 that limit ERK activation but do not regulate NF-kB
activation downstream of TLR4, DOK3 negatively regulates both
ERK and NF-kB activation. Taken together, DOK3 represents
a novel negative regulator of LPS signaling in macrophages.
The signal for ubiquitination of DOK3 is likely unique to TLR
signaling. Generally, PTK-elicited phosphorylation events trigger
protein degradation through the ubiquitination pathways [28]. For
example, V-Src targets DOK1 for ubiquitin-mediated proteaso-
mal degradation during cellular transformation [29]. Here we
have shown that Src kinases phosphorylate DOK3 but that this
phosphorylation event is not required for DOK3 degradation.
Furthermore, DOK3 is constitutively phosphorylated in adherent
macrophages possibly due to integrin activation [30], which is in
contrast to B cells, where DOK3 phosphorylation occurs in
response to BCR stimulation [20]. However, DOK3-phosphory-
lation may regulate protein-protein interactions in response to
TLR signals. Ubiquitination and subsequent degradation of
DOK3 has not been described in B cells; thus, ubiquitin-mediated
degradation of DOK3 may be uniquely associated with TLR
signaling or to the myeloid lineage.
DOK3 contributes to the regulation of ERK activation
downstream of LPS signaling and the formation of a Grb2-
SOS1-DOK3 complex appears to limit ERK activation. Our
findings reveal a different mechanism of ERK regulation from
a previous report showing that DOK3 over-expression in non-
hematopoietic cells inhibits ERK activation downstream of
phosphotyrosine kinases (PTK) by promoting the sequestering of
Grb2, thus limiting Grb2 and SOS1-mediated activation of Ras
[19]. Our data show that SOS1 levels decrease in parallel to
DOK3 after LPS stimulation and that SOS1 is degraded in the
lysosome in a DOK3-dependent manner after LPS stimulation.
Additionally, SOS1 levels are increased in BMM-derived from
DOK3-deficient mice suggesting that DOK3 negatively regulates
SOS1 levels. We propose that the ubiquitination and degradation
of DOK3 promotes the degradation of SOS1 thereby limiting
ERK activation (Figure 9). Mechanistically, DOK3 could bring
SOS1 into proximity to an E3 ligase or could shuttle SOS1 into
the proteosome itself and is the subject of future studies.
Regulation of Ras activation by SOS1 degradation represents
a novel mechanism of Ras and ERK regulation. SOS1 mutations
have recently been reported to occur in Noonan’s syndrome and
Hereditary Gingival Fibromastosis Type 1 disease, both of which
are associated with abnormal Ras activation [31]. Additionally,
exposure to environmental pollutants and toxins significantly
induces SOS1 expression and contributes to cellular proliferation
in a manner analogous to Ras activation mutations [32]. We
Figure 8. DOK3-deficient macrophages are more sensitive to endotoxin tolerance. Tolerance was induced in wild type and DOK3-deficient
BMM with the indicated dose of LPS (10 or 100 ng/ml) overnight, followed by resting in fresh media for 2 h and re-challenged with the same dose of
LPS for 12 h in the presence of Brefeldin A. Intracellular TNFa production was assessed with flow cytometry after the cells were fixed, permeabilized,
and stained with anti-TNFa. Results are represented (A) by one-parameter histograms (green is control staining, red is naı ¨ve cells, and blue is tolerant
cells) or (B) by MFI (mean fluorescence intensity) of TNFa-producing population and representative of two independent experiments. (C) Tolerant
wild type and DOK3-deficient BMM or naı ¨ve cells were stimulated with 1 mg/ml LPS and immunoblotted for SHIP1, IRAK-M, SOCS1, and GAPDH.
Densitometry of the bands was determined using image J normalizing to GAPDH, and the relative numerical value was written below the band. Data
are representative of three independent experiments.
doi:10.1371/journal.pone.0039967.g008
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controlled during cellular states of environmental stimuli including
LPS. DOK3 remains stable during tolerance and could serve to
sequester SOS1 and Grb2 thereby limiting activation by a different
mechanism than during the initial LPS response. Indeed, during
endotoxin tolerance, stable DOK3 expression correlates with
inhibition of ERK activation during LPS re-challenge, whereas
DOK3-deficiency leads to enhanced LPS tolerance due to
increased sensitivity to the initial LPS stimulation. Thus, ERK
activation is regulated in part by the degradation of DOK3, as
compared to DOK1 and DOK2 which negatively regulate ERK
activity by recruiting Ras-GAP [17]. Alternatively, degradation of
DOK3 may indirectly intersect the Tpl2-mediated ERK activa-
tion signaling pathway, as LPS stimulation induced more rapid
degradation of IkBa in DOK3-deficient BMM compared to wild
type, which can cause more NF-kB1 p105 degradation and the
release of Tpl2 from the ABIN-2-NF-kB1-Tpl2 complex [25,33].
Although DOK3 is required to limit initial ERK activation
following LPS stimulation, it is not required for the development of
endotoxin tolerance. Indeed, cells deficient in DOK3 showed
increased sensitivity to LPS induced tolerance in vitro. The LPS
tolerance in DOK3-deficient cells was accompanied by significant
upregulation of SHIP1, IRAK-M, and SOCS1 suggesting that the
enhanced ERK and NF-kB activation, induced by the initial LPS
stimulation, primes the cells for rapid induction of tolerance upon
re-challenge. IRAK-M deficiency leads to enhanced ERK
activation and cytokine responses in naı ¨ve cells but prevents the
induction of tolerance [8]. Likewise, SHIP1 is required for
endotoxin tolerance [9]. Like DOK3, SHIP1 is also required to
limit CpG induced cytokine responses in macrophages and is also
critical for CpG induced tolerance [34]. Similarly, SOCS-1 is
required for tolerance and mice deficient for SOCS1 are more
highly susceptible to LPS than wild type [10,14]. Additionally, in
tolerant DOK3-deficient cells, SOS1 is significantly upregulated
compared to wild type cells suggesting that DOK3 also negatively
regulates SOS1 during tolerance. Thus, DOK3 negatively
regulates the expression of key endotoxin tolerance effecter
proteins.
Here we have shown that DOK3 also negatively regulates
cytokine responses to LPS. In the naı ¨ve state, DOK3-deficiency
leads to increased IL-1b and TNFa compared to wild type.
Previous studies have demonstrated that LPS tolerance is
associated with increased expression of IL-10 in vitro and suggest
that anti-inflammatory IL-10 may contribute to endotoxin
tolerance [33]. LPS increases IL-10 production in monocytes
from septic patients as well as monocyte cell lines [33,35]. IL-1b is
also reported to induce tolerance in vivo, as mice treated daily with
doses of IL-1b were refractory to LPS stimulation [36] and U937
LPS-tolerant macrophages were associated with an increased
secretion of IL-1b [37]. We speculate that the enhanced TNFa,
IL-10 and IL-1b contribute to the enhanced sensitivity of
DOK3
2/2 BMM to tolerance.
In sum, we have identified DOK3 as a negative regulator of
LPS signaling in macrophages. LPS treatment induces DOK3
ubiquitination and degradation and SOS1 degradation leading to
ERK activation. In the absence of DOK3, early ERK activation
occurs as well as increased SOS1 expression and NF-kB
activation. This data indicates that DOK3 is a proximal negative
regulator of TLR signaling (Figure 9). Additionally, DOK3 may
serve to prevent LPS tolerance by negatively regulating TNFa, IL-
10, IL-1b, SHIP-1, IRAK-M, and SOCS1. DOK3 therefore plays
a significant role in the maintenance of immune cell activation in
response to TLR stimuli.
Materials and Methods
Mice
129S1/SvImJ mice were obtained from commercial vendors
and housed at the Oklahoma Medical Research Foundation
(OMRF). DOK3-deficient 129S1/SvImJ mice were kindly pro-
vided by Pier Paolo Pandolfi (Departments of Medicine and
Pathology, Harvard Medical School) [26]. Animals were main-
tained according to the guidelines of the Association for
Assessment and Accreditation of Laboratory Animal Care at
OMRF.
Figure 9. Proposed model of DOK3 regulation of TLR4 signaling and endotoxin tolerance. In naı ¨ve cells, DOK3 associates with Grb2 and
SOS1 constitutively. Upon LPS stimulation, DOK3 becomes ubiquitinated, possibly by Cbl-b, and degraded, thereby releasing Grb2. SOS1 is also
degraded in a DOK3-dependent manner thus limiting ERK activation. In LPS-induced tolerant cells, DOK3 and SOS1 expression remains stable during
repeated LPS challenge. DOK3 may limit ERK activation during tolerance by binding to and sequestering Grb2 and SOS1. Mediators of tolerance
including IRAK-M, SHIP1, and SOCS1 are upregulated.
doi:10.1371/journal.pone.0039967.g009
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The following antibodies were used: DOK1, DOK2, DOK3,
Cbl-b, SHIP1 and SOS1 (Santa Cruz Biotechnology); GST, ERK,
PERK, Grb2, IRAK-M, SOCS1, IkBa, and cleaved caspase3
(Cell Signaling Technology); GAPDH (Abcam); ubiquitin (Cov-
ance); 4G10-argarose conjugate (phosphotyrosine) and Flag M2
(Upstate Biotechnology); fluorescently-conjugated secondary anti-
bodies (Invitrogen), PE-conjugated anti-TNFa (EBioscience).
Escherichia coli O55:B5 LPS (Sigma) was used for in vitro assays
and Salmonella typhosa (Sigma) LPS was used for the in vivo survival
analysis.
Macrophage Cell Culture
RAW 264.7 cells were purchased from ATCC and maintained
in complete medium. Bone marrow macrophage (BMM) cells
were flushed from bones and cultured as previously described [38].
After 2 days, non-adherent BMM cells were collected and
transferred at a density of 5 610
6 and cultured for an additional
2 to 5 days. shRNA lentiviral particles (Santa Cruz Biotechnology)
were used according to the manufacturer’s protocol. Briefly,
RAW264.7 macrophage cells were cultured to 50% confluence,
the media was removed and replaced with 1 ml of Polybrene
(5 mg/ml)/media mixture per well (for 12-well plate). The cells
were infected by adding the 6 ml DOK3 shRNA lentiviral particles
(1610
6 infectious units of virus (IFU)) and stable clones expressing
the DOK3 shRNA were selected with Puromycin (5 mg/ml).
pCMV-FLAG- DOK3 transfection was performed by nucleofec-
tion following the Amaxa protocol for RAW264.7 macrophage
cells.
Construction of cDNA Plasmids
pCMV-FLAG-DOK3 was constructed by subcloning mouse
DOK3 cDNA (IMAGE No. 40126241) into pCMV-FLAG
(Sigma). GST-CBL-Uba construct was made by subcloning the
Uba domain (887–928 aa) of Cbl-b (IMAGE No. 40129800) into
the glutathione S-transferase (GST) fusion protein expression
vector pGEX4T3 by PCR (Open Biosystems). The generated
constructs were confirmed by DNA sequencing.
TLR Stimulation and Endotoxin Tolerance
BMM were stimulated with TLR ligands for the indicated time.
Conditioned media and cell lysates collected. TNFa, IL-6, IL-10
and IL-1b in duplicate supernatants were measured by enzyme-
linked immunosorbent assay (eBioscience). For tolerance, BMM
were pretreated with 1 mg/ml LPS from E. coli for 18 hours, rested
in fresh media for two hours, then re-stimulated with LPS. For
intracellular TNFa staining, cells were stimulated for 12 h in the
presence of 10 mg/ml Brefeldin A (Sigma), fixed and permeabi-
lized, followed by blocking with 2.4G2 and staining with
phycoerythrin-labeled antibody to TNFa (eBioscience). Cells were
analyzed by flow cytometry (FACS Calibur).
Immunoprecipitation
Cells lysates were prepared using ice-cold radioimmunopreci-
pitation assay (RIPA) buffer as previously described [39].
Immunoprecipitation were performed by incubating the pre-
cleared cell lysates with primary antibody on ice for 1 h and then
adding protein A or G beads at 4uC for 1 h with rotation. The
beads were washed and the immunoprecipitation complexes were
dissolved in SDS-PAGE sample buffer for SDS-PAGE. The
proteins were transferred to nitrocellulose or PVDF membranes,
immunoblotted with the appropriate antibodies, and visualized
with the enhanced chemiluminescence (ECL) system (Pierce).
Expression, Purification and Pulldown Assays of GST
Fusion Protein
GST alone or GST-Cbl-Uba fusion protein were expressed in
E. coli (JM109) and purified by affinity glutathione-agarose beads
as described previously [1]. The protein-bead complexes (15–
20 mg protein) were incubated with cell lysates (,1 mg) at 4uC for
2 hours with rotation. The beads were washed three times with
RIPA buffer and dissolved in SDS-PAGE sample buffer for
western blotting.
Immunofluorescent Confocal Microscopy
BMM cells were in 8- or 16-well Permanox chamber slides
(Costar) and serum starved for 3 h. Following stimulation for
indicated time with LPS, cells were fixed with 1% paraformalde-
hyde in PBS, permeabilized with 0.05% saponin in PBS, blocking
with antibody (2.4G2), and incubated with primary and secondary
antibodies. Samples were viewed with either a Zeiss LSM510
(OMRF) or a Leica SP2 (OUHSC) confocal microscope and the
images were analyzed with LSM confocal software.
In vivo Assays
Wild type or DOK3
2/2 mice (n=5/group) were challenged
i.p. with 70 mg/kg LPS in PBS and monitored twice daily for 7
days. Serum was collected by terminal heart puncture from wild
type or DOK3
2/2 mice (n=3/group) one hour following i.p.
challenge with 5 mg/kg LPS in PBS.
Statistical Analysis
Statistical analyses were analyzed by Student’s t-test or survival
analysis (Mantel-Cox Chi square) and performed with GraphPad
Prism Plus software.
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